Gemtuzumab Ozogamicin (GO)

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
06013
Idarubicin and Ara-C in combination with Gemtuzumab-Ozogamycin (IAGO) for untreated patients, with or without an HLA identical sibling, with high risk MDS or AML developing after a preceding period with MDS during 6 months duration : a phase II study.
06012
Gemtuzumab Ozogamycin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61 - 75 years old with previously untreated AML : a randomized phase III trial (AML-17) of the EORTC - LG and the GIMEMA-ALWP
06031
Gemtuzumab ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy : a randomized phase II/III trial (AML-19) of the EORTC-LG and GIMEMA-ALWP.

Back to Protocol section